Selected research
Market Structure
Global TB Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global TB Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for TB Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for TB Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for TB Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for TB Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of TB Vaccines include China National Biotec Group, Sanofi Pasteur, Merck & Co.,Inc, Statens Serum Institut, Serum Institute, Japan BCG Laboratory, InterVax Ltd, India Pvt. Ltd and GreenSignal, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global TB Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of TB Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents TB Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the TB Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.
TB Vaccines Segment by Company
China National Biotec Group
Sanofi Pasteur
Merck & Co.,Inc
Statens Serum Institut
Serum Institute
Japan BCG Laboratory
InterVax Ltd
India Pvt. Ltd
GreenSignal
Bio Pharma Limited
TB Vaccines Segment by Type
Immunotherapeutic Vaccines
Booster Vaccines
Others
TB Vaccines Segment by Application
Private Clinics
Research Institutes
Hospitals
TB Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TB Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of TB Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TB Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the TB Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of TB Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of TB Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of TB Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Immunotherapeutic Vaccines
- Booster Vaccines
- Others
Applications
- Private Clinics
- Research Institutes
- Hospitals
Companies covered
- China National Biotec Group
- Sanofi Pasteur
- Merck & Co.,Inc
- Statens Serum Institut
- Serum Institute
- Japan BCG Laboratory
- InterVax Ltd
- India Pvt. Ltd
- GreenSignal
- Bio Pharma Limited
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global TB Vaccines Market Size, 2021 VS 2025 VS 2032
- 1.3 Global TB Vaccines Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global TB Vaccines Sales Estimates and Forecasts (2021-2032)
- 1.5 Global TB Vaccines Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global TB Vaccines Market Dynamics
- 2.1 TB Vaccines Industry Trends
- 2.2 TB Vaccines Industry Drivers
- 2.3 TB Vaccines Industry Opportunities and Challenges
- 2.4 TB Vaccines Industry Restraints
3 TB Vaccines Market by Manufacturers
- 3.1 Global TB Vaccines Revenue by Manufacturers (2021-2026)
- 3.2 Global TB Vaccines Sales by Manufacturers (2021-2026)
- 3.3 Global TB Vaccines Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global TB Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global TB Vaccines Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global TB Vaccines Manufacturers, Product Type & Application
- 3.7 Global TB Vaccines Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global TB Vaccines Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 TB Vaccines Players Market Share by Revenue in 2025
- 3.8.3 2025 TB Vaccines Tier 1, Tier 2, and Tier 3
4 TB Vaccines Market by Type
- 4.1 TB Vaccines Type Introduction
- 4.1.1 Immunotherapeutic Vaccines
- 4.1.2 Booster Vaccines
- 4.1.3 Others
- 4.2 Global TB Vaccines Sales by Type
- 4.2.1 Global TB Vaccines Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global TB Vaccines Sales by Type (2021-2032)
- 4.2.3 Global TB Vaccines Sales Market Share by Type (2021-2032)
- 4.3 Global TB Vaccines Revenue by Type
- 4.3.1 Global TB Vaccines Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global TB Vaccines Revenue by Type (2021-2032)
- 4.3.3 Global TB Vaccines Revenue Market Share by Type (2021-2032)
5 TB Vaccines Market by Application
- 5.1 TB Vaccines Application Introduction
- 5.1.1 Private Clinics
- 5.1.2 Research Institutes
- 5.1.3 Hospitals
- 5.2 Global TB Vaccines Sales by Application
- 5.2.1 Global TB Vaccines Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global TB Vaccines Sales by Application (2021-2032)
- 5.2.3 Global TB Vaccines Sales Market Share by Application (2021-2032)
- 5.3 Global TB Vaccines Revenue by Application
- 5.3.1 Global TB Vaccines Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global TB Vaccines Revenue by Application (2021-2032)
- 5.3.3 Global TB Vaccines Revenue Market Share by Application (2021-2032)
6 Global TB Vaccines Sales by Region
- 6.1 Global TB Vaccines Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global TB Vaccines Sales by Region (2021-2032)
- 6.2.1 Global TB Vaccines Sales by Region (2021-2026)
- 6.2.2 Global TB Vaccines Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America TB Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America TB Vaccines Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe TB Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe TB Vaccines Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific TB Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific TB Vaccines Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa TB Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa TB Vaccines Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global TB Vaccines Revenue by Region
- 7.1 Global TB Vaccines Revenue by Region
- 7.1.1 Global TB Vaccines Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global TB Vaccines Revenue by Region (2021-2026)
- 7.1.3 Global TB Vaccines Revenue by Region (2027-2032)
- 7.1.4 Global TB Vaccines Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America TB Vaccines Revenue (2021-2032)
- 7.2.2 North America TB Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe TB Vaccines Revenue (2021-2032)
- 7.3.2 Europe TB Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific TB Vaccines Revenue (2021-2032)
- 7.4.2 Asia-Pacific TB Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa TB Vaccines Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa TB Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 China National Biotec Group
- 8.1.1 China National Biotec Group Company Information
- 8.1.2 China National Biotec Group Business Overview
- 8.1.3 China National Biotec Group TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 China National Biotec Group TB Vaccines Product Portfolio
- 8.1.5 China National Biotec Group Recent Developments
- 8.2 Sanofi Pasteur
- 8.2.1 Sanofi Pasteur Company Information
- 8.2.2 Sanofi Pasteur Business Overview
- 8.2.3 Sanofi Pasteur TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sanofi Pasteur TB Vaccines Product Portfolio
- 8.2.5 Sanofi Pasteur Recent Developments
- 8.3 Merck & Co.,Inc
- 8.3.1 Merck & Co.,Inc Company Information
- 8.3.2 Merck & Co.,Inc Business Overview
- 8.3.3 Merck & Co.,Inc TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck & Co.,Inc TB Vaccines Product Portfolio
- 8.3.5 Merck & Co.,Inc Recent Developments
- 8.4 Statens Serum Institut
- 8.4.1 Statens Serum Institut Company Information
- 8.4.2 Statens Serum Institut Business Overview
- 8.4.3 Statens Serum Institut TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Statens Serum Institut TB Vaccines Product Portfolio
- 8.4.5 Statens Serum Institut Recent Developments
- 8.5 Serum Institute
- 8.5.1 Serum Institute Company Information
- 8.5.2 Serum Institute Business Overview
- 8.5.3 Serum Institute TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Serum Institute TB Vaccines Product Portfolio
- 8.5.5 Serum Institute Recent Developments
- 8.6 Japan BCG Laboratory
- 8.6.1 Japan BCG Laboratory Company Information
- 8.6.2 Japan BCG Laboratory Business Overview
- 8.6.3 Japan BCG Laboratory TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Japan BCG Laboratory TB Vaccines Product Portfolio
- 8.6.5 Japan BCG Laboratory Recent Developments
- 8.7 InterVax Ltd
- 8.7.1 InterVax Ltd Company Information
- 8.7.2 InterVax Ltd Business Overview
- 8.7.3 InterVax Ltd TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 InterVax Ltd TB Vaccines Product Portfolio
- 8.7.5 InterVax Ltd Recent Developments
- 8.8 India Pvt. Ltd
- 8.8.1 India Pvt. Ltd Company Information
- 8.8.2 India Pvt. Ltd Business Overview
- 8.8.3 India Pvt. Ltd TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 India Pvt. Ltd TB Vaccines Product Portfolio
- 8.8.5 India Pvt. Ltd Recent Developments
- 8.9 GreenSignal
- 8.9.1 GreenSignal Company Information
- 8.9.2 GreenSignal Business Overview
- 8.9.3 GreenSignal TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 GreenSignal TB Vaccines Product Portfolio
- 8.9.5 GreenSignal Recent Developments
- 8.10 Bio Pharma Limited
- 8.10.1 Bio Pharma Limited Company Information
- 8.10.2 Bio Pharma Limited Business Overview
- 8.10.3 Bio Pharma Limited TB Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Bio Pharma Limited TB Vaccines Product Portfolio
- 8.10.5 Bio Pharma Limited Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 TB Vaccines Value Chain Analysis
- 9.1.1 TB Vaccines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 TB Vaccines Production Mode & Process
- 9.2 TB Vaccines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 TB Vaccines Distributors
- 9.2.3 TB Vaccines Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst